A clinical stage gene and cell therapy company
focused on curative intent in solid tumor cancer
THE NEXT GENERATION OF
CANCER PLATFORM TECHNOLOGY
CISH: a novel immune
checkpoint
T cell genetic engineering
for solid tumor
T CELL THERAPY IN SOLID TUMOR
THE UNMET MEDICAL NEED
INTIMA BIOSCIENCE CLINICAL TRIAL
Intima Bioscience is conducting a clinical trial at the University of Minnesota Masonic Cancer Center with its Molecular and Cell Therapy (MCT) GMP gene and cell therapy manufacturing facility.

A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune Checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Gastro-Intestinal Cancer.

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

PUBLICATIONS
A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL)
AAV Capsid Chimeras with Enhanced Infectivity reveal a core element in the AAV Genome critical for both Cell Transduction and Capsid Assembly
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade
TECHNOLOGY PLATFORM
T Cells
CISH Checkpoint Target
CRISPR Genetic Engineering
Autologous
3rd generation neoantigen-enriched, genetically-engineered, Tumor Infiltrating Lymphocytes (TIL)
Allogeneic / Off-The-Shelf
TCR therapy for solid tumor
genetically-enigneered, iPS-derived T cells
Next Generation Checkpoint
CISH is a novel intra-cellular immune checkpoint and an important negative regulator of T-cell signaling and function
New York City | Cambridge UK
Intima Bioscience, Inc.
3 Columbus Circle, New York, NY 10019, USA
Building 250, Babraham Research Campus,
Cambridge, CB22 3AT, UK